Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Immix Biopharma, Inc. filed an amended annual report mainly to correct the date of the auditor’s report, with no changes to its previously reported 2025 financials. The clinical-stage biotech, focused on cell therapies for AL amyloidosis and immune-mediated diseases, reported a 2025 net loss of $29.4 million, wider than $21.7 million in 2024, driven by higher research and development and general and administrative expenses.
Despite continued losses, Immix ended 2025 with cash and cash equivalents of $93.9 million and short-term investments of $6.5 million, lifting total assets to $104.8 million and stockholders’ equity to $93.8 million. The company raised $107.4 million net from equity offerings and an at-the-market program, and also benefited from an $8 million CIRM grant, with about $4.6 million reimbursed by year-end. Management believes existing cash plus expected grant disbursements will fund operations for at least 12 months from the filing date, even as Immix advances its pipeline and continues to generate negative operating cash flow.
Immix Biopharma, Inc. entered into Amendment No. 1 to its At The Market Offering Agreement with Citizens JMP Securities, LLC. The amended arrangement allows Immix to sell shares of common stock from time to time in an at-the-market program with an aggregate offering price of up to $100,000,000 under its effective Form S-3 shelf registration.
Citizens JMP Securities will act as sales agent and use commercially reasonable efforts to place shares within company instructions and applicable Nasdaq and regulatory limits. Immix will pay a 3.0% commission on gross sales proceeds and reimburse specified expenses up to $50,000. The filing also includes a legal opinion from Blank Rome LLP on the validity of the shares.
Immix Biopharma, Inc. proposes to offer up to $100,000,000 of Common Stock in an at-the-market offering pursuant to an ATM Agreement with Citizens JMP Securities, LLC, as amended on March 25, 2026.
The ATM permits sales from time to time on the Nasdaq Capital Market or through other permitted methods. Citizens will receive a 3.0% commission on gross sales and will be deemed an underwriter for Securities Act purposes. Proceeds to the company will vary based on actual shares sold and market prices.
Shares outstanding were 52,964,549 as of March 20, 2026, and the prospectus illustration shows up to 63,941,497 shares outstanding after the offering assuming sale of 10,976,948 shares at $9.11 per share.
Immix Biopharma, Inc. files its annual report detailing rapid progress of lead CAR‑T candidate NXC‑201 and key financings. NXC‑201 targets relapsed/refractory AL amyloidosis, a life‑threatening disease with no FDA‑approved therapies as of March 2026, and has shown high complete response rates and organ improvements in early‑phase trials with manageable safety.
The program now holds FDA Orphan Drug, RMAT and Breakthrough Therapy designations, plus European orphan status, and is being advanced in the U.S. Phase 1b/2 NEXICART‑2 trial with a planned BLA filing after final readout. Immix strengthened its balance sheet through a December 2025 underwritten offering raising approximately $100.0 million and a September 2025 private placement raising about $9.3 million, and is supported by an $8 million CIRM grant, of which $6.2 million had been reimbursed by March 20, 2026.
The company reports an aggregate market value of non‑affiliate equity of $35.7 million as of June 30, 2025, with 52,964,549 shares of common stock outstanding as of March 20, 2026. It highlights substantial ongoing losses, significant future capital needs, clinical, regulatory and manufacturing risks, heavy dependence on third parties, and potential dilution as central risk factors.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report collective ownership of 2,812,230 shares of Immix Biopharma common stock, representing 5.3% of the class as shown in the filing dated 03/13/2026.
The filing states the shares are held by entities over which Millennium Management LLC and related managers have shared voting and dispositive power. A joint filing agreement among the three parties is attached and the disclosure is signed on 03/19/2026.
Saturn V Capital Management LP and Xiaoying Tian report beneficial ownership of 3,693,585 shares of Immix Biopharma common stock, representing 6.97% of the company’s shares. The shares are held in pooled investment vehicles and managed accounts advised by Saturn V, and no single client owns at least five percent of the company. Both Saturn V and Ms. Tian have shared power to vote and dispose of these shares but each disclaims beneficial ownership. The reported percentage is based on 52,955,130 shares outstanding as of January 8, 2026, as disclosed in an Immix Biopharma Form S-3.
Immix Biopharma, Inc. received a Schedule 13G filing from Janus Henderson Group plc, which reports beneficial ownership of 3,921,568 shares of Immix common stock, representing 7.4% of the class as of 12/31/2025.
All of these shares are held in managed portfolios advised by various Janus Henderson asset management subsidiaries, which exercise investment and voting discretion but do not have rights to dividends or sale proceeds. The filing is certified as a passive, ordinary-course investment, not intended to change or influence control of Immix Biopharma.
Immix Biopharma, Inc. has filed a shelf registration statement that would allow it to offer and sell up to $750,000,000 of various securities over time. The mixed shelf covers common stock, preferred stock, debt securities, warrants and units, which may also be issued upon conversion or exercise of other registered securities.
Specific terms, prices and amounts for each issuance will be set in future prospectus supplements, and sales may occur through underwriters, dealers, agents or direct transactions. The company currently intends to use net proceeds primarily for working capital and general corporate purposes. Its common stock trades on The Nasdaq Capital Market under the symbol IMMX, and there were 52,955,130 shares of common stock outstanding as of January 8, 2026.
Immix Biopharma is a clinical-stage biopharmaceutical company focused on CAR-T cell therapies, led by its NXC-201 program in AL amyloidosis and other serious diseases. It qualifies as an emerging growth company and a smaller reporting company, which allows reduced reporting and disclosure requirements under U.S. securities laws.
Immix Biopharma director Dr. Nancy T. Chang reported an equity award dated 11/21/2025. She received a stock option (right to buy common stock) for 39,643 shares at an exercise price of $4.33 per share, exercisable until 11/21/2035.
The option will vest in 36 equal monthly installments following the grant date, subject to her continued service and a stock option agreement. After the reported transaction, she beneficially owned 421,940 shares of common stock directly and 496,940 shares indirectly through Robinhood II, LP, where she is general manager and may be deemed to beneficially own those securities while disclaiming ownership beyond her pecuniary interest.